News Updates

GSK reported that data from its Phase 3 trial evaluating MenABCWY, its five-in-one meningococcal vaccine, showed the candidate met all of the study's primary endpoints, was well tolerated and had a safety profile similar to Bexsero, or MenB, and Menveo, or MenACWY. GSK's MenABCWY, if approved, could offer the best protection against invasive meningococcal disease as it combines those two other meningococcal vaccines' antigenic components that may result in increased vaccine uptake. PMLive (UK) (3/14)